Home/ Stocks/ JAZZ

Jazz Pharmaceuticals, Inc.

JAZZ XNAS

$225.79 -1.17 (-0.52%) ▼ 15-min delayed

Open

$228.73

High

$230.00

Low

$223.34

Volume

741.3K

Market Cap

$14.17B

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 2.9K Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$1.07B	$293.10M	$4.73
Q3 2025	$1.13B	$251.41M	$4.14
Q2 2025	$1.05B	$-718,470,000	$-11.74
Q1 2025	$897.84M	$-92,541,000	$-1.52

Earnings & Analyst Ratings

Next Earnings: Mon, Aug 3, 2026

Calendar →

Related Market News

No specific coverage for JAZZ yet. Check out our latest market news or earnings calendar.

Get JAZZ Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Jazz Pharmaceuticals, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.